Sci Rep:预防性抗生素在预防发热性中性粒细胞减少中的效用

2021-05-06 AlexYang MedSci原创

最近,有研究人员调查了预防性抗生素在使用G-CSF治疗去势抵抗性前列腺癌(CRPC)期间预防发热性中性粒细胞减少症(FN)中的疗效情况。

最近,有研究人员调查了预防抗生素在使用G-CSF治疗去势抵抗性前列腺癌(CRPC)期间预防发热性中性粒细胞减少症(FN)中的疗效情况

研究人员回顾性地研究了2012年5月至2018年8月期间给予56名CRPC患者的443个周期的卡巴他赛治疗。他们进行了统计分析来确定预防性G-CSF和抗生素的组合使用与单独的预防性G-CSF相比,是否能更有效地预防FN。

研究人员在所有443个周期中都进行了预防性的PEG-G-CSF或G-CSF。只有氟喹诺酮类药物被用作预防性抗生素,并在328个周期中使用(74.0%)。结果表明,5个周期发生了FN(1.1%)。FN阴性组有327个周期(74.6%)使用预防性抗生素,FN阳性组只有1个周期(20.0%)使用预防性抗生素。卡方检验表明,与未接受预防性抗生素的组别相比,接受预防性抗生素的组别FN的发生率明显降低(P=0.017)

使用预防性抗生素组和不使用预防性抗生素组中的卡巴他赛周期数和FN发生周期的累积发生率

另外,与单独的预防性G-CSF相比,预防性G-CSF和抗生素联用明显抑制了FN的发生

原始出处:

Keitaro Watanabe , Takeo Kosaka , Hiroshi Hongo et al. Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer. Sci Rep. Apr 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2003881, encodeId=7772200388143, content=<a href='/topic/show?id=3f43e621302' target=_blank style='color:#2F92EE;'>#粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76213, encryptionId=3f43e621302, topicName=粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Thu May 13 12:36:15 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034854, encodeId=7e6b2034854c9, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jun 04 19:36:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981861, encodeId=55e919818615c, content=<a href='/topic/show?id=311822199b6' target=_blank style='color:#2F92EE;'>#中性粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22199, encryptionId=311822199b6, topicName=中性粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Jul 22 02:36:15 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963862, encodeId=43ec9638625f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73835475130, createdName=我是谁是我, createdTime=Sun May 09 06:22:35 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296758, encodeId=2a8d1296e5871, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sat May 08 10:36:15 CST 2021, time=2021-05-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2003881, encodeId=7772200388143, content=<a href='/topic/show?id=3f43e621302' target=_blank style='color:#2F92EE;'>#粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76213, encryptionId=3f43e621302, topicName=粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Thu May 13 12:36:15 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034854, encodeId=7e6b2034854c9, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jun 04 19:36:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981861, encodeId=55e919818615c, content=<a href='/topic/show?id=311822199b6' target=_blank style='color:#2F92EE;'>#中性粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22199, encryptionId=311822199b6, topicName=中性粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Jul 22 02:36:15 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963862, encodeId=43ec9638625f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73835475130, createdName=我是谁是我, createdTime=Sun May 09 06:22:35 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296758, encodeId=2a8d1296e5871, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sat May 08 10:36:15 CST 2021, time=2021-05-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2003881, encodeId=7772200388143, content=<a href='/topic/show?id=3f43e621302' target=_blank style='color:#2F92EE;'>#粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76213, encryptionId=3f43e621302, topicName=粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Thu May 13 12:36:15 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034854, encodeId=7e6b2034854c9, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jun 04 19:36:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981861, encodeId=55e919818615c, content=<a href='/topic/show?id=311822199b6' target=_blank style='color:#2F92EE;'>#中性粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22199, encryptionId=311822199b6, topicName=中性粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Jul 22 02:36:15 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963862, encodeId=43ec9638625f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73835475130, createdName=我是谁是我, createdTime=Sun May 09 06:22:35 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296758, encodeId=2a8d1296e5871, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sat May 08 10:36:15 CST 2021, time=2021-05-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2003881, encodeId=7772200388143, content=<a href='/topic/show?id=3f43e621302' target=_blank style='color:#2F92EE;'>#粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76213, encryptionId=3f43e621302, topicName=粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Thu May 13 12:36:15 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034854, encodeId=7e6b2034854c9, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jun 04 19:36:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981861, encodeId=55e919818615c, content=<a href='/topic/show?id=311822199b6' target=_blank style='color:#2F92EE;'>#中性粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22199, encryptionId=311822199b6, topicName=中性粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Jul 22 02:36:15 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963862, encodeId=43ec9638625f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73835475130, createdName=我是谁是我, createdTime=Sun May 09 06:22:35 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296758, encodeId=2a8d1296e5871, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sat May 08 10:36:15 CST 2021, time=2021-05-08, status=1, ipAttribution=)]
    2021-05-09 我是谁是我

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2003881, encodeId=7772200388143, content=<a href='/topic/show?id=3f43e621302' target=_blank style='color:#2F92EE;'>#粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76213, encryptionId=3f43e621302, topicName=粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Thu May 13 12:36:15 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034854, encodeId=7e6b2034854c9, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jun 04 19:36:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981861, encodeId=55e919818615c, content=<a href='/topic/show?id=311822199b6' target=_blank style='color:#2F92EE;'>#中性粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22199, encryptionId=311822199b6, topicName=中性粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Jul 22 02:36:15 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963862, encodeId=43ec9638625f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73835475130, createdName=我是谁是我, createdTime=Sun May 09 06:22:35 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296758, encodeId=2a8d1296e5871, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sat May 08 10:36:15 CST 2021, time=2021-05-08, status=1, ipAttribution=)]

相关资讯

Eur Urol Focus:前列腺活检与前列腺钬激光剜除术之间的短时间间隔与较差的围手术期结果有关

目前还没有关于经直肠前列腺活检(PB)和前列腺钬激光切除术(HoLEP)之间的时间间隔对围手术期结果影响的数据。

Eur Radiol:前列腺癌根治术时如何评价切缘是否有浸润?

根治性前列腺切除术后阳性手术切缘的存在会大大增加患者肿瘤复发的风险。尽管达到切缘阴性仍然是RP的主要目标,但保留神经血管束和膜性尿道功能也同样重要。

盘点:前列腺癌与治疗进展(六)

【1】Prostate:沙利度胺抑制人前列腺基质细胞生长和平滑肌收缩:LUTS的新疗法?

Eur Urol:前列腺癌盆腔照射后的机器人辅助膀胱切除术与体内尿路分流

前列腺癌(PCa)的放射治疗(RT)因晚期泌尿系统副作用事件(UAEs)发生率高而造成使用负担。机器人辅助膀胱切除术(RAC)与体内尿路分流术(ICUD)治疗高等级泌尿副作用的可行性尚未评估。

Sci Rep:用于检测去势抵抗性前列腺癌患者治疗诱发的神经内分泌分化的新型非侵入性标志物

神经内分泌性前列腺癌(NEPC)是去势抵抗性前列腺癌(CRPC)的一种高度侵袭性变体,通常在使用雄性激素途径抑制剂治疗后通过神经内分泌分化出现。

Eur Urol:前列腺特异性膜抗原和氟尿嘧啶转运体基因与原发性前列腺癌的不同临床特征和分子亚型有关

在美国,基于8F-氟尿嘧啶的正电子发射断层扫描(PET)成像推荐用于前列腺癌治疗后的生化复发(BCR)。然而,基于前列腺特异性膜抗原(PSMA)的PET成像在世界范围内更为普遍,且由国际指南的支持,目